Skip to main content

Table 2 Best tumor responses of patients with low and high baseline HBV DNA level

From: Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

Tumor response

All patients (n = 70)

Baseline HBV DNA ≤ 2000 IU/mL (n = 48)

Baseline HBV DNA > 2000 IU/mL (n = 22)

Complete response (CR)

1 (1.4)

1 (2.1)

0

Partial response (PR)

14 (20.0)

10 (20.8)

4 (18.2)

Stable disease (SD)

36 (51.4)

25 (52.1)

11 (50.0)

Progressive disease (PD)

19 (27.1)

12 (25.0)

7 (31.8)

ORR (CR + PR)Δ

15 (21.4)

11 (22.9)

4 (18.2)

DCR (CR + PR + SD)*

61 (72.9)

36 (75.0)

15 (68.2)

  1. ORR objective response rate, DCR disease control rate
  2. ΔFisher’s exact test, P = 0.761; *Pearson χ2 = 0.355, P = 0.552